GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma
- First Posted Date
- 2009-09-24
- Last Posted Date
- 2016-08-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT00983658
A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2017-06-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00977067
A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT00975182
A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-09-10
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT00974584
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy
- First Posted Date
- 2009-09-09
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT00973011
A Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids
- First Posted Date
- 2009-09-03
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT00971035
A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT00968981
A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus
- First Posted Date
- 2009-08-20
- Last Posted Date
- 2016-08-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 238
- Registration Number
- NCT00962832
A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT00960960
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-08-14
- Last Posted Date
- 2015-01-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT00959647
© Copyright 2024. All Rights Reserved by MedPath